CD47-blocking antibody confers metabolic benefits against obesity

For tumor immunotherapy, CD47-blocking antibody is a potential antibody drug but its role in protecting obesity is not clear.

The researchers suggest that obesity upregulates CD47 expression while exercise downregulates CD47 expression in skeletal muscle.

The authors show that administration of CD47-blocking antibody in mice prevents HFD-induced weight gain and glucose intolerance, enhances exercise capacity, and improves body composition and skeletal muscle mitochondrial function. 

Targeting CD47 with a blocking antibody confers multiple metabolic benefits through AMPK signaling in skeletal muscles. Mechanistically, the CD47-blocking antibody reduces the phosphorylation of heat shock protein 90α (HSP90α) to activate AMPK in skeletal muscle.

These findings reveal a potential therapeutic strategy for obesity-related metabolic disorders.

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00162-4

https://sciencemission.com/CD47-blocking-antibody-and-obesity